147 related articles for article (PubMed ID: 27514543)
21. HES6 promotes prostate cancer aggressiveness independently of Notch signalling.
Carvalho FL; Marchionni L; Gupta A; Kummangal BA; Schaeffer EM; Ross AE; Berman DM
J Cell Mol Med; 2015 Jul; 19(7):1624-36. PubMed ID: 25864518
[TBL] [Abstract][Full Text] [Related]
22. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.
Jiang YG; Luo Y; He DL; Li X; Zhang LL; Peng T; Li MC; Lin YH
Int J Urol; 2007 Nov; 14(11):1034-9. PubMed ID: 17956532
[TBL] [Abstract][Full Text] [Related]
23. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
Prowald A; Cronauer MV; von Klot C; Eilers T; Rinnab L; Herrmann T; Spindler KD; Montenarh M; Jonas U; Burchardt M
Prostate; 2007 Dec; 67(16):1751-60. PubMed ID: 17929268
[TBL] [Abstract][Full Text] [Related]
24. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
25. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
[TBL] [Abstract][Full Text] [Related]
26. Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt".
Fisher RR; Pleskow HM; Bedingfield K; Miyamoto DT
Expert Rev Mol Diagn; 2020 Feb; 20(2):245-254. PubMed ID: 31814454
[No Abstract] [Full Text] [Related]
27. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
28. Quercetin modulates Wnt signaling components in prostate cancer cell line by inhibiting cell viability, migration, and metastases.
Baruah MM; Khandwekar AP; Sharma N
Tumour Biol; 2016 Oct; 37(10):14025-14034. PubMed ID: 27495232
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
30. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review).
Katoh M; Katoh M
Int J Mol Med; 2007 Feb; 19(2):273-8. PubMed ID: 17203201
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
32. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
Yang X; Chen MW; Terry S; Vacherot F; Chopin DK; Bemis DL; Kitajewski J; Benson MC; Guo Y; Buttyan R
Cancer Res; 2005 Jun; 65(12):5263-71. PubMed ID: 15958572
[TBL] [Abstract][Full Text] [Related]
33. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
34. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.
Nguyen DP; Li J; Yadav SS; Tewari AK
BJU Int; 2014 Aug; 114(2):168-76. PubMed ID: 24215139
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells.
Liu XH; Kirschenbaum A; Weinstein BM; Zaidi M; Yao S; Levine AC
Biochem Biophys Res Commun; 2010 Apr; 394(3):715-20. PubMed ID: 20227393
[TBL] [Abstract][Full Text] [Related]
36. RPE specification in the chick is mediated by surface ectoderm-derived BMP and Wnt signalling.
Steinfeld J; Steinfeld I; Coronato N; Hampel ML; Layer PG; Araki M; Vogel-Höpker A
Development; 2013 Dec; 140(24):4959-69. PubMed ID: 24227655
[TBL] [Abstract][Full Text] [Related]
37. Wnt signaling controls the fate of mesenchymal stem cells.
Ling L; Nurcombe V; Cool SM
Gene; 2009 Mar; 433(1-2):1-7. PubMed ID: 19135507
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
39. Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?
Dees C; Distler JH
Exp Dermatol; 2013 Nov; 22(11):710-3. PubMed ID: 24118232
[TBL] [Abstract][Full Text] [Related]
40. Mitotic and mitogenic Wnt signalling.
Niehrs C; Acebron SP
EMBO J; 2012 Jun; 31(12):2705-13. PubMed ID: 22617425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
